Sonia Blanco Mejia1,2, Mark Messina3, Siying S Li1,4, Effie Viguiliouk1,2, Laura Chiavaroli1,2, Tauseef A Khan1,2, Korbua Srichaikul1, Arash Mirrahimi1, John L Sievenpiper1,2,5,6,7, Penny Kris-Etherton8, David J A Jenkins1,2,5,6,7. 1. Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. 2. Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital,Toronto, ON, Canada. 3. Soy Nutrition Institute, St. Louis, MO, USA. 4. School of Medicine, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada. 5. Division of Endocrinology and Metabolism, Department of Medicine, St. Michael's Hospital, Toronto, ON, Canada. 6. Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada. 7. Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. 8. Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA.
Abstract
BACKGROUND: Certain plant foods (nuts and soy protein) and food components (viscous fibers and plant sterols) have been permitted by the FDA to carry a heart health claim based on their cholesterol-lowering ability. The FDA is currently considering revoking the heart health claim for soy protein due to a perceived lack of consistent LDL cholesterol reduction in randomized controlled trials. OBJECTIVE: We performed a meta-analysis of the 46 controlled trials on which the FDA will base its decision to revoke the heart health claim for soy protein. METHODS: We included the 46 trials on adult men and women, with baseline circulating LDL cholesterol concentrations ranging from 110 to 201 mg/dL, as identified by the FDA, that studied the effects of soy protein on LDL cholesterol and total cholesterol (TC) compared with non-soy protein. Two independent reviewers extracted relevant data. Data were pooled by the generic inverse variance method with a random effects model and expressed as mean differences with 95% CI. Heterogeneity was assessed and quantified. RESULTS: Of the 46 trials identified by the FDA, 43 provided data for meta-analyses. Of these, 41 provided data for LDL cholesterol, and all 43 provided data for TC. Soy protein at a median dose of 25 g/d during a median follow-up of 6 wk decreased LDL cholesterol by 4.76 mg/dL (95% CI: -6.71, -2.80 mg/dL, P < 0.0001; I2 = 55%, P < 0.0001) and decreased TC by 6.41 mg/dL (95% CI: -9.30, -3.52 mg/dL, P < 0.0001; I2 = 74%, P < 0.0001) compared with non-soy protein controls. There was no dose-response effect or evidence of publication bias for either outcome. Inspection of the individual trial estimates indicated most trials (∼75%) showed a reduction in LDL cholesterol (range: -0.77 to -58.60 mg/dL), although only a minority of these were individually statistically significant. CONCLUSIONS: Soy protein significantly reduced LDL cholesterol by approximately 3-4% in adults. Our data support the advice given to the general public internationally to increase plant protein intake. This trial was registered at clinicaltrials.gov as NCT03468127.
BACKGROUND: Certain plant foods (nuts and soy protein) and food components (viscous fibers and plant sterols) have been permitted by the FDA to carry a heart health claim based on their cholesterol-lowering ability. The FDA is currently considering revoking the heart health claim for soy protein due to a perceived lack of consistent LDL cholesterol reduction in randomized controlled trials. OBJECTIVE: We performed a meta-analysis of the 46 controlled trials on which the FDA will base its decision to revoke the heart health claim for soy protein. METHODS: We included the 46 trials on adult men and women, with baseline circulating LDL cholesterol concentrations ranging from 110 to 201 mg/dL, as identified by the FDA, that studied the effects of soy protein on LDL cholesterol and total cholesterol (TC) compared with non-soy protein. Two independent reviewers extracted relevant data. Data were pooled by the generic inverse variance method with a random effects model and expressed as mean differences with 95% CI. Heterogeneity was assessed and quantified. RESULTS: Of the 46 trials identified by the FDA, 43 provided data for meta-analyses. Of these, 41 provided data for LDL cholesterol, and all 43 provided data for TC. Soy protein at a median dose of 25 g/d during a median follow-up of 6 wk decreased LDL cholesterol by 4.76 mg/dL (95% CI: -6.71, -2.80 mg/dL, P < 0.0001; I2 = 55%, P < 0.0001) and decreased TC by 6.41 mg/dL (95% CI: -9.30, -3.52 mg/dL, P < 0.0001; I2 = 74%, P < 0.0001) compared with non-soy protein controls. There was no dose-response effect or evidence of publication bias for either outcome. Inspection of the individual trial estimates indicated most trials (∼75%) showed a reduction in LDL cholesterol (range: -0.77 to -58.60 mg/dL), although only a minority of these were individually statistically significant. CONCLUSIONS: Soy protein significantly reduced LDL cholesterol by approximately 3-4% in adults. Our data support the advice given to the general public internationally to increase plant protein intake. This trial was registered at clinicaltrials.gov as NCT03468127.
Authors: G Hori; M F Wang; Y C Chan; T Komatsu; Y Wong; T H Chen; K Yamamoto; S Nagaoka; S Yamamoto Journal: Biosci Biotechnol Biochem Date: 2001-01 Impact factor: 2.043
Authors: D J Jenkins; C W Kendall; E Vidgen; V Vuksan; C J Jackson; L S Augustin; B Lee; M Garsetti; S Agarwal; A V Rao; G B Cagampang; V Fulgoni Journal: Metabolism Date: 2000-11 Impact factor: 8.694
Authors: Paraskevi Massara; Andreea Zurbau; Andrea J Glenn; Laura Chiavaroli; Tauseef A Khan; Effie Viguiliouk; Sonia Blanco Mejia; Elena M Comelli; Victoria Chen; Ursula Schwab; Ulf Risérus; Matti Uusitupa; Anne-Marie Aas; Kjeld Hermansen; Inga Thorsdottir; Dario Rahelić; Hana Kahleová; Jordi Salas-Salvadó; Cyril W C Kendall; John L Sievenpiper Journal: Diabetologia Date: 2022-08-26 Impact factor: 10.460
Authors: David J A Jenkins; Sonia Blanco Mejia; Laura Chiavaroli; Effie Viguiliouk; Siying S Li; Cyril W C Kendall; Vladmir Vuksan; John L Sievenpiper Journal: J Am Heart Assoc Date: 2019-06-27 Impact factor: 5.501
Authors: Giusy Rita Caponio; David Q-H Wang; Agostino Di Ciaula; Maria De Angelis; Piero Portincasa Journal: Int J Mol Sci Date: 2020-12-28 Impact factor: 5.923